PFIZER INC. will spend about $5.4 billion to purchase Global Blood Therapeutics (GBT) as the pharmaceutical giant continues to invest some of the cash influx reaped during the Covid-19 pandemic.
The company said on Monday the acquisition would boost its capabilities in rare hematology. Global Blood makes Oxybryta tablets for treating sickle cell disease. Its sales reached about $195 million last year.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.